Description: Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Home Page: www.celyad.com
Axis Business Park
Mont-Saint-Guibert,
1435
Belgium
Phone:
32 1 039 41 00
Officers
| Name | Title |
|---|---|
| Mr. Michel E. J. Lussier BME, M.B.A., M.S., MS BME | Co-Founder & Executive Director |
| Mr. Matthew R. Kane | Chief Executive Officer |
| Mr. David Georges | Vice President of Finance & Administration |
| Sara Zelkovic | Communications & Investor Relations Director |
| Ms. An Phan | Head of Legal |
| Mr. Hannes Iserentant | Head of Intellectual Property |
| Mr. Eytan Breman | Head of R&D |
| Mr. Philippe Dechamps | Corporate Secretary |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Energy |
|---|---|
| GIC Group: | Energy |
| GIC Industry: | Oil, Gas & Consumable Fuels |
| GIC Sub-Industry: | Coal & Consumable Fuels |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 118.5508 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 17 |